From November 5 to 6, 2016, the second HDACi summit was successfully held in Chengdu, Sichuan. HDACi summit is a large-scale academic gathering in the field of blood tumors organized by CHIPSCREEN BIOSCIENCES since the listing of Chidamide in February 2015. The summit is held once a year to exchange the latest academic progress of HDACi at home and abroad and provide a platform for blood oncologists to learn and exchange.

The summit invited Professor Ma Jun from Harbin Institute of Hematologic Diseases and Tumors, Professor Shen Zhixiang from Ruijin Hospital affiliated to Shanghai Jiao Tong University, Professor Liu Ting from West China Hospital, Professor Shi Yuankai from Tumor Hospital affiliated to Chinese Academy of Medical Sciences, Professor Li Junmin from Ruijin hospital affiliated to Shanghai Jiao Tong University, Professor Jin Jie from the first affiliated hospital of Zhejiang University Medical School, Professor Lin Tongyu from Zhongshan University Tumor Prevention Center, Professor Wang Jianmin from Changhai hospital affiliated to the second Military Medical University, Professor Wang Huaqing from Tianjin People's Hospital affiliated to Nankai University, Professor Wang Jianxiang from Hematology Institute affiliated to Chinese Academy of Medical Sciences, Professor Liu Qizhi from Southern Hospital of Southern Medical University, Professor Jiang Wenqi from Zhongshan University's Tumor Prevention Center, and Professor Wu Depei from the first Affiliated Hospital of Suzhou University, who are served as the president of the conference on different topics respectively. Experts giving lectures and commenting on blood tumors are famous both at home and abroad. The summit attracted more than 200 blood tumor experts from all over the country to attend.

Dr. Lu, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, gave a wonderful report on the progress of global clinical research in Chidamide for the conference. He pointed out that Chidamide had obvious long-term OS benefits for PTCL patients from Chidamide's registered research and analysis of clinical application data after the market. In the future, the precise treatment assisted by molecular typing or the path to realize long-term benefits for tumor patients will eventually shift from the past single drug treatment to the era of combined treatment. Professor Owen A. O’Connor, the director of the Columbia University Medical Center and the lymphatic system malignant tumor center of New York Presbyterian Hospital and the professor of medicine and experimental therapeutics, and 21 other top experts from home and abroad made presentations for the conference. At the meeting, experts conducted in-depth discussions and exchanges from the basic research of HDACi to the interpretation of T-cell lymphoma consensus and treatment, then to B cell lymphoma, stem cell transplantation pretreatment, and clinical research on leukemia.

Finally, Professor Ma Jun of Harbin Hematological Tumor Research Institute summarized the summit. Since Chidamide was listed in early 2015, he has carried out a number of works and studies, and there are more than 1500 cases of peripheral T-cell lymphoma and NK/T-cell lymphoma. Some experts also made research reports on rare T-cell lymphomas such as liver γδ T-cell lymphomas and enteropathy-related T-cell lymphomas. On the B cell lymphoma, several experts introduced their respective clinical studies, which will also be the focus of future research. In epigenetics, the combination of demethylation and deacetylation inhibitors in the treatment of NK/T-cell lymphoma is also a new direction. The application of Chidamide in AML, hematopoietic stem cell transplantation and other hematological diseases has also opened up a new road. It is mentioned that China has entered an aging stage, and more attention should be paid to the treatment and exploration of related hematological diseases in the elderly, such as MM, MDS and other aspects. In addition, experts also explored beat maintenance therapy. In the course of one and a half days, all experts had in-depth exchanges and heated discussions. They also hoped that Chidamide would enter the medical insurance system to benefit lymphoma and hematologic patients, and to work together with love in the future.